Clinical Scorecard: Umbilical Cord Methadone and Buprenorphine Concentrations in Relation to Neonatal Opioid Withdrawal Severity
At a Glance
Category
Detail
Condition
Neonatal opioid withdrawal syndrome (NOWS) following prenatal methadone or buprenorphine exposure
Key Mechanisms
NOWS involves central nervous system irritability, gastrointestinal distress, and autonomic dysfunction. The mechanisms behind medication-related differences in NOWS severity remain uncertain.
Target Population
Pregnant individuals with opioid use disorder treated continuously with methadone or buprenorphine for at least 30 days before delivery, and their neonates born at 34 weeks’ gestation or later
Care Setting
Multisite prospective cohort examining prenatal medication exposure, umbilical cord drug concentrations, and neonatal withdrawal severity
Key Highlights
Severe NOWS occurred more frequently with methadone than buprenorphine exposure: 55.6% versus 27.5%; adjusted odds ratio 3.42 (95% CI, 1.17-9.96).
Umbilical cord methadone and EDDP concentrations were positively correlated with maternal methadone dose.
Maternal buprenorphine dose was not significantly associated with cord buprenorphine or norbuprenorphine concentrations.
Maternal medication doses and cord opioid concentrations were comparable between neonates with severe and nonsevere NOWS.
Guideline-Based Recommendations
Diagnosis
Severe NOWS was defined by pharmacologic treatment, high Finnegan scores, or failure to meet Eat-Sleep-Console criteria.
Assessment used site-specific protocols based on modified Finnegan scoring or the Eat-Sleep-Console approach.
Management
Monitoring & Follow-up
The study assessed NOWS using modified Finnegan scoring or Eat-Sleep-Console criteria, according to site protocols.
Umbilical cord tissue collected at birth was analyzed by mass spectrometry for methadone, buprenorphine, and their primary metabolites.
Risks
Methadone exposure was associated with higher adjusted odds of severe NOWS than buprenorphine exposure in this cohort.
The study found no association between maternal dose or cord drug concentrations and NOWS severity.
The authors note that medication selection was not randomized and that the modest sample size limited causal analysis.
Patient & Prescribing Data
The cohort included 92 pregnancies and 94 neonates; 53 neonates had methadone exposure and 40 had buprenorphine exposure. Participants had continuous treatment for at least 30 days before delivery and delivered at 34 weeks’ gestation or later.
Severe NOWS affected 41 neonates (43.6%). Maternal methadone and buprenorphine doses did not differ significantly between severe and nonsevere NOWS groups. The article reports no association between maternal MOUD dose and severe NOWS and supports individualized dosing based on maternal clinical stability.
